What is the equivalent dose of Extampza (oxycodone) to OxyContin (oxycodone) 10mg extended release?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

OxyContin 10mg to Extampza Equivalent Dose

Extampza 10mg is equivalent to OxyContin 10mg—both formulations contain oxycodone extended-release and should be dosed identically on a milligram-to-milligram basis.

Direct Dose Conversion

Both OxyContin and Extampza (Xtampza ER) are extended-release oxycodone formulations designed for twice-daily dosing, and they share the same active ingredient at equivalent potency 1.

  • The conversion is 1:1 (mg to mg) because both products deliver the same opioid (oxycodone) in extended-release formulations 2
  • OxyContin 10mg = Extampza 10mg in terms of opioid content and morphine milligram equivalents (MME) 1
  • Using the CDC conversion factor of 1.5 for oxycodone, both 10mg formulations equal 15 MME per dose, or 30 MME daily when dosed twice daily 1

Key Formulation Differences

While the dose equivalence is 1:1, the formulations differ significantly in their physical properties:

  • Extampza uses DETERx microsphere-in-capsule technology that retains extended-release properties even when crushed or chewed, unlike OxyContin 3, 4, 5
  • Extampza capsules can be opened and sprinkled on soft food or administered via feeding tube, which OxyContin tablets cannot 4
  • Both maintain 12-hour dosing intervals with similar pharmacokinetic profiles when taken as directed 3

Clinical Considerations for Conversion

When switching from OxyContin 10mg to Extampza 10mg:

  • No dose adjustment is required for the direct switch between these formulations 2
  • The 10mg dose represents a relatively low opioid burden (30 MME/day), well below the 50 MME/day threshold where CDC recommends careful reassessment 1
  • Both formulations are indicated for opioid-tolerant patients with chronic pain requiring around-the-clock analgesia, not for acute pain 1

Important Safety Caveats

  • Extended-release opioids should never be used for acute pain or as-needed analgesia—they are exclusively for chronic pain in opioid-tolerant patients 1
  • Tablets/capsules must be swallowed whole (though Extampza contents can be sprinkled); crushing OxyContin destroys the extended-release mechanism and risks overdose 5
  • Equianalgesic conversions are estimates and cannot account for individual variability in genetics and pharmacokinetics 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Oxycodone: a pharmacological and clinical review.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2007

Research

Oxycodone extended release capsules for the treatment of chronic pain.

Expert review of neurotherapeutics, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.